A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.

Psychometric validation of the psoriasis symptoms and impacts measure (P-SIM): a novel patient-reported outcome instrument for patients with plaque psoriasis, using reported data from the BE RADIANT phase 3b trial. Erythrodermic psoriasis (EP) is a rare variant of psoriasis characterized by a severe, in some cases life-threatening, clinical course.[1] EP affects about 1%-2% of psoriasis patients with generalized erythema and scaling covering the entire body surface.[2] In recent years, numerous therapeutic alternatives are available for EP treatment; however, there are still no standardized international guidelines, and most biologics are used on the basis of clinical practice, case reports, or small case series.[1] Bimekizumab is a novel humanized monoclonal antibody that neutralizes both interleukin (IL)-17A and IL-17F.[3] IL-17A and IL-17F have been shown to be functionally dysregulated in different immune-mediated inflammatory diseases such as psoriasis and psoriatic arthritis.[3] Given the overlapping biology of these two cytokines, Bimekizumab was developed in order to provide a greater depth of clinical response rather than IL-17A inhibition alone.[3] It has been recently approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.[3] Bimekizumab use in EP, as the case of the other biological drugs, is still off label. Following the onset of COVID-19 pandemic, the patient suspended outpatient follow-ups and adalimumab treatment, experiencing a progressive worsening of the disease. [Extracted from the article]